Leading Interventional Cardiologists Join CorFlow’s Scientific Advisory Board

Leading Interventional Cardiologists Join CorFlow’s Scientific Advisory Board

Baar, Switzerland, May 8th 2018

CorFlow Therapeutics AG today announced that leading interventional cardiologists from Europe, Japan and the United States have joined the CorFlow Scientific Advisory Board (SAB).

The CorFlow SAB will advice the company on technology developments and clinical strategies. The SAB will secure that the CorFlow Controlled Flow Infusion (CoFI™) technology serves a real need for the hundred of thousands of acute heart attack patients who every year require improved coronary microcirculation after primary percutaneous coronary intervention (PPCI, also known as “stenting”).

The CorFlow SAB consists of the following interventional cardiologists:

Prof. Stephan Windecker (Chairman), Inselspital, Bern, Switzerland

Prof. Takashi Akasaka, Wakayama University Hospital, Wakayama, Japan

Prof. Alexandra Lansky, Yale University Hospital, New Haven, CT, United States of America

Dr. Azeem Latib, San Rafaele University Hospital, Milan, Italy

Jon H. Hoem, CorFlow’s CEO & Co-Founder, commented: “We are very excited to have world-leading interventional cardiologists supporting CorFlow in our efforts. The structure of the SAB reflects the global interest we are receiving for our breakthrough technologies which have the potential to improve coronary care and outcomes.”

CorFlow has since its foundation in June 2016 worked to document that the CoFI™ technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation in the cathlab fitting the workflow for acute heart attack (STEMI) patients. The company is now preparing to file the dossier for the First-in-Man clinical trial named the MOCA (Microvascular Obstruction with the CoFI™ System Assessment) trial.

CorFlow Therapeutics will present the recent findings using the CoFI™ technology during the EuroPCR conference in Paris, France, May 21-24.

The company has been selected to present during the Innovation Day on Monday, the “Out-of-the-Box” session on Wednesday and during the moderated e-poster session “Novel approaches to coronary physiology”.

We look forward to see you in Paris!

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *

5 + 17 =